Comparison of the Outcomes between Systematic Lymph Node Dissection and Lobe-Specific Lymph Node Dissection for Stage I Non-small Cell Lung Cancer

This study compares the surgical and long-term outcomes, including disease-free survival (DFS), overall survival (OS), and cancer-specific survival (CSS), between lobe-specific lymph node dissection (L-SND) and systematic lymph node dissection (SND) among patients with stage I non-small cell lung ca...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostics (Basel) 2023-04, Vol.13 (8), p.1399
Main Authors: Huang, Ching-Chun, Tang, En-Kuei, Shu, Chih-Wen, Chou, Yi-Ping, Goan, Yih-Gang, Tseng, Yen-Chiang
Format: Article
Language:English
Subjects:
Care and treatment
Chi-square test
Comparative analysis
Diaphragm (Anatomy)
Dissection
Independent sample
L-SND
Lung cancer
Lung cancer, Non-small cell
Lymphatic system
Medical prognosis
Metastasis
Mortality
NSCLC
Patient outcomes
Patients
Pulmonary arteries
Thoracic surgery
Tomography
Tumors
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study compares the surgical and long-term outcomes, including disease-free survival (DFS), overall survival (OS), and cancer-specific survival (CSS), between lobe-specific lymph node dissection (L-SND) and systematic lymph node dissection (SND) among patients with stage I non-small cell lung cancer (NSCLC). In this retrospective study, 107 patients diagnosed with clinical stage I NSCLC undergoing video-assisted thoracic surgery lobectomy (exclusion of the right middle lobe) from January 2011 to December 2018 were enrolled. The patients were assigned to the L-SND ( = 28) and SND ( = 79) groups according to the procedure performed on them. Demographics, perioperative data, and surgical and long-term oncological outcomes were collected and compared between the L-SND and SND groups. The mean follow-duration was 60.6 months. The demographic data and surgical outcomes and long-term oncological outcomes were not significantly different between the two groups. The 5-year OS of the L-SND and SND groups was 82% and 84%, respectively. The 5-year DFS of the L-SND and SND groups was 70% and 65%, respectively. The 5-year CSS of the L-SND and SND groups was 80% and 86%, respectively. All the surgical and long-term outcomes were not statistically different between the two groups. L-SND showed comparable surgical and oncologic outcomes with SND for clinical stage I NSCLC. L-SND could be a treatment choice for stage I NSCLC.
ISSN:2075-4418
2075-4418
DOI:10.3390/diagnostics13081399